Compare ASTRAZENECA PHARMA with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GLENMARK PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GLENMARK PHARMA ASTRAZENECA PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 163.3 14.6 1,116.9% View Chart
P/BV x 45.8 2.4 1,909.1% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ASTRAZENECA PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
GLENMARK PHARMA
Mar-19
ASTRAZENECA PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,278712 179.6%   
Low Rs883484 182.5%   
Sales per share (Unadj.) Rs228.4349.6 65.3%  
Earnings per share (Unadj.) Rs10.432.8 31.6%  
Cash flow per share (Unadj.) Rs16.344.3 36.7%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs98.8198.6 49.7%  
Shares outstanding (eoy) m25.00282.17 8.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.71.7 276.7%   
Avg P/E ratio x104.218.2 571.8%  
P/CF ratio (eoy) x66.413.5 492.9%  
Price / Book Value ratio x10.93.0 363.6%  
Dividend payout %06.1 0.0%   
Avg Mkt Cap Rs m27,008168,625 16.0%   
No. of employees `0001.412.0 11.3%   
Total wages/salary Rs m1,53520,561 7.5%   
Avg. sales/employee Rs Th4,210.98,196.0 51.4%   
Avg. wages/employee Rs Th1,132.21,708.1 66.3%   
Avg. net profit/employee Rs Th191.1768.5 24.9%   
INCOME DATA
Net Sales Rs m5,71098,655 5.8%  
Other income Rs m1232,081 5.9%   
Total revenues Rs m5,833100,736 5.8%   
Gross profit Rs m46315,858 2.9%  
Depreciation Rs m1473,259 4.5%   
Interest Rs m03,346 0.0%   
Profit before tax Rs m43811,335 3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m1793,756 4.8%   
Profit after tax Rs m2599,250 2.8%  
Gross profit margin %8.116.1 50.4%  
Effective tax rate %40.833.1 123.2%   
Net profit margin %4.59.4 48.4%  
BALANCE SHEET DATA
Current assets Rs m3,20966,968 4.8%   
Current liabilities Rs m2,07040,211 5.1%   
Net working cap to sales %20.027.1 73.6%  
Current ratio x1.61.7 93.1%  
Inventory Days Days7283 86.8%  
Debtors Days Days3581 43.0%  
Net fixed assets Rs m79033,322 2.4%   
Share capital Rs m50282 17.7%   
"Free" reserves Rs m2,41955,770 4.3%   
Net worth Rs m2,46956,052 4.4%   
Long term debt Rs m035,738 0.0%   
Total assets Rs m4,605132,888 3.5%  
Interest coverage xNM4.4-  
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.20.7 167.0%   
Return on assets %5.69.5 59.4%  
Return on equity %10.516.5 63.6%  
Return on capital %17.717.8 99.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m30062,998 0.5%   
Fx outflow Rs m2,01522,859 8.8%   
Net fx Rs m-1,71540,140 -4.3%   
CASH FLOW
From Operations Rs m8813,242 0.7%  
From Investments Rs m-94-6,990 1.3%  
From Financial Activity Rs mNA-7,387 0.0%  
Net Cashflow Rs m-6-2,971 0.2%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 0.3 6.9 4.3%  
FIIs % 15.7 34.4 45.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   12,856 56,727 22.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  SUVEN LIFESCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare ASTRAZENECA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex Jumped 505 Points Today(Closing)

Indian share markets continued momentum and ended their session on a strong note today.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks(Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

It's Time to Book Profits(Fast Profits Daily)

Nov 27, 2020

In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.

How the New Margins Will Impact You(Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

Is this Sector the Best Contrarian Bet Right Now?(Profit Hunter)

Nov 23, 2020

The risk reward ratio in this beaten down sector may have finally turned for the better.

The Price of Dying, the Cost of Living(The Honest Truth)

Nov 20, 2020

Ajit Dayal presents a cost benefit analysis of the various types of response to covid around the world.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Dec 1, 2020 03:36 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS